Newsfeeds Archive - Spark Newswire

1 minute read

‘PDS Biotech’s Survival Benefit Is Absurdly Overstated’ – By Adam Feuerstein/ STAT News

May 16, 11:03 AM

https://www.statnews.com/2024/05/16/pds-biotech-survival-benefit/ This is the online edition of Adam's Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it

PDSB

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

March 27, 12:31 PM

Gainers Stoke Therapeutics (NASDAQ:STOK) shares increased by 46.1% to $15.03 during Wednesday’s regular session. The company’s market cap…

AKLI

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s Pre-Market Session

By Benzinga Insights

March 27, 9:05 AM

Gainers Lixte Biotechnology (NASDAQ:LIXT) shares moved upwards by 67.2% to $3.77 during Wednesday’s pre-market session. The market value…

AKLI

4 minute read

Earnings

Earnings Scheduled For March 27, 2024

By Benzinga Insights

March 27, 5:02 AM

Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million.

AGAE

2 minute read

Analyst Ratings

Analyst Expectations for PDS Biotechnology’s Future

By Benzinga Insights

November 15, 3:01 PM

Over the past 3 months, 4 analysts have published their opinion on PDS Biotechnology (NASDAQ:PDSB) stock. These analysts…

PDSB

12 minute read

Earnings

Earnings Scheduled For November 14, 2023

By Benzinga Insights

November 14, 9:23 AM

Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million.

ACXP

1 minute read

Earnings

A Preview Of PDS Biotechnology’s Earnings

By Benzinga Insights

November 13, 11:01 AM

PDS Biotechnology (NASDAQ:PDSB) is set to give its latest quarterly earnings report on Tuesday, 2023-11-14. Here’s what investors…

PDSB

3 minute read

PDS Biotech Announces Updated Survival Data From NCI-Led Phase 2 Clinical Trial Of PDS0101-Based Triple Combination Therapy In Advanced HPV16-Positive Cancer Patients which Show 75% Survival Of ICI Naïve Patients At 36 Months

By Benzinga Newsdesk

November 9, 9:27 AM

75% of immune checkpoint inhibitor (ICI) naïve patients remain alive at 36 months; published median overall survival (OS) in similar patients is 7-11 months12-month survival rate in ICI resistant patients is 72%Median OS

PDSB

3 minute read

PDS Biotech Announces Preliminary Biomarker Study Results In Subset Of Advanced HPV-Positive Head And Neck Cancer Patients At ESMO

By Happy Mohamed

October 23, 8:16 AM

Combination of PDS0101 and KEYTRUDA® appears to lead to changes towards a TH1 predominant cytokine profile reported to be associated with improved killer T cell activity Lowered CD8 T cells in peripheral

PDSB